Introduction
Retinoids, generally referring to the entire set of compounds including both naturally occurring and synthetic vitamin A (retinol) metabolites and analogs, exert their cellular effects via interactions with six nuclear receptors, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs; each containing a, b, and g subtypes) (Laudet and Gronemeyer, 2002; Gronemeyer et al., 2004) . Retinoids are physiological regulators of essential biological processes that include cell growth, differentiation and apoptosis Clagett-Dame and DeLuca, 2002; Gavalas, 2002) . The strong cell differentiation potential of retinoids has led to their use in both chemotherapy and chemoprevention of human cancers (Hong and Sporn, 1997; Hansen et al., 2000; Sun and Lotan, 2002 ). The prototype of successful 'cancer differentiation therapy' is the all-trans RA (ATRA) therapy of acute promyelocytic leukemia (APL) caused by a leukemogenic RAR fusion protein (PML-RARa) (de The et al., 1991; Kakizuka et al., 1991; Pandolfi et al., 1991) .
In addition to inducing differentiation, ATRA and all RARa-selective agonists also trigger apoptosis in the human APL cell line, NB4, and in leukemic blasts of patients by activating the TRAIL (TNFSF10) death signaling pathway . It remains unclear if death induction by RARa agonist is a specific feature of PML-RARa-positive APL cells and if there is any requirement for RXR agonists. These studies demonstrated a cell-autonomous paracrine action mode of the TRAIL pathway, which operates independently of the well-established role of TRAIL in tumor surveillance by the innate immune system (Takeda et al., 2001 (Takeda et al., , 2004 . This is evident also from the TNFSF10 knockout that increases tumor susceptibility without displaying any other overt phenotype Sedger et al., 2002) . Importantly, the cellautonomous action of TRAIL and its receptors can be drug targeted and recent results have demonstrated that several anticancer drugs or treatment paradigms invoke activation of this tumor-selective death pathway. Indeed, it appears that distinct antiproliferative signaling pathways (retinoids, interferons) and novel types of drugs for cancer therapy (HDAC inhibitors) all converge on the TRAIL pathway (Clarke et al., 2004; Altucci et al., 2005; Insinga et al., 2005; Nebbioso et al., 2005) . TRAIL initiates apoptosis through DR4 (TNFRSF10A) (Pan et al., 1997) and DR5 (TNFRSF10B) (MacFarlane et al., 1997; Walczak et al., 1997) , which contain a cytoplasmic death domain (DD) . Upon ligation by TRAIL, its receptors form trimers and recruit to their death domains Fasassociated death domain (FADD), which in turn recruits procaspase-8 through its death effector domain (DED), and result in the formation of a death-inducing signaling complex (DISC) (Muzio et al., 1998; Kischkel et al., 2000; Sprick et al., 2002) .
Two cell types have been identified based on differences in signal propagation downstream of the DISC formation (Scaffidi et al., 1998; Suliman et al., 2001) . In type-I cells, FADD-recruited procaspase-8 auto-processes itself through self-oligomerization to the active protease (Muzio et al., 1998; Salvesen and Dixit, 1999) , leading to rapid cleavage of downstream effector caspases before the loss of mitochondrial membrane potential. In type-II cells, where DISC formation is poor, activated caspase-8 truncates the proapoptotic bcl-2 family member, Bid (Wang et al., 1996) , which then translocates to mitochondria, resulting in the loss of mitochondrial membrane potential. In this case, the mitochondria function as 'amplifiers' to initiate the caspase cascade via release of cytochrome c (Luo et al., 1998) , which binds to Apaf-1 (Zou et al., 1997) , followed by the recruitment and oligomerization of procaspase-9 (Srinivasula et al., 1998) . In the resulting complex, termed 'apoptosome' (Zou et al., 1999) , oligomerized procaspase-9 auto-activates itself (Srinivasula et al., 1998; Shiozaki et al., 2002) and triggers cleavage of the downstream executioner caspase-3 (Li et al., 1997) .
In the present study, we have investigated first the implications of RAR and RXR in leukemia cell differentiation and apoptosis to reveal possible differences between leukemia cells containing the leukemogenic PML-RARa fusion protein (NB4 cells, APL blasts) and those devoid of the fusion protein. For this we chose the HL60 subclone PLB985 (Tucker et al., 1987; Drexler et al., 2003) , which has normal diploid karyotype and can differentiate into granulocytes or monocytes. We observed that, in contrast to NB4 cells, the RARs and RXRs of PLB985 display distinct functionalities in regulating cell growth, maturation and apoptosis. Subsequently, in an attempt to identify master switches downstream of RAR/RXR-dependent apoptosis signaling, we used a retrovirus-mediated insertion mutagenesis approach and generated a mutant cell line (WY-1) that is defective in RA-induced differentiation and apoptosis, and notably, also in TRAIL-induced apoptosis. Tracking the inserted virus led to the identification of a poorly annotated huge 328 kb gene, RAM (retinoic acid modulator), which is selectively expressed in the myelomonocytic lineage and is negatively regulated by RA. Downregulation of RAM by siRNA promoted RA-induced differentiation and TRAIL-triggered apoptosis in PLB985 and WY-1 cells, identifying RAM as a novel RA-dependent modulator of myeloid differentiation and death. Interestingly, overexpression of the 109 amino-acid-coding region of RAM did not alter differentiation or apoptosis of the parental cells, suggesting that RAM RNA may have functions unrelated to its hypothetical translation product.
Results
Distinct roles of RAR and RXR on PLB985 cell proliferation, differentiation and apoptosis RARa-selective retinoids are sufficient to induce differentiation and apoptosis of NB4 cells and APL patients' blasts (Chen et al., 1996; . In PLB985 myelomonoblastic cells, an RARa agonist (BMS753) alone decreased cell proliferation (Figure 1a) owing to G1 arrest (data not shown) and induces differentiation ( Figure 1b) but not cell death ( Figure 1c ). The cotreatment with a RXR agonist (SR11237, 'SR'), which itself had no effect, induced a synergistic differentiation which is followed by a post-maturation apoptosis (Figure 1a-c ). These results demonstrate that PLB985 cell differentiation can be triggered by just RAR activation, whereas apoptosis requires the actions of both RAR and RXR. In the subsequent studies we used 9-cis RA, which is a pan-RAR and pan-RXR agonist that induces both PLB985 differentiation and death ( Figure 1d ). Co-resistance to 9-cis RA and TRAIL W Yin et al
Retrovirus insertional mutation of RAM generates 9-cis RA-resistant PLB985 cells To identify key mediators of 9-cis RA-induced apoptosis we used a mutational approach and infected PLB985 cells with an amphotropic retrovirus (LXSN) (Miller and Rosman, 1989) . We established a 9-cis RA-resistant PLB985 mutant cell line (WY-1) (Figure 2a ), which is defective for RA-induced differentiation as revealed by NBT reduction (Figure 2b ) and CD11c expression (the intensity of the signal in WY-1 cells was only 25% of that seen with WT cells, Figure 2c ). The impaired differentiation of WY-1 cells correlated with the absence of the G1 arrest seen in the WT cells treated with 9-cis RA ( Figure 2d ). Importantly, like the parent cells, WY-1 cells remain fully competent for monocytic differentiation induced by 1a,25-dihydroxyvitamin D3 (Figure 2b) , demonstrating that the virus insertion targeted a pathway that is selectively required for RA-induced differentiation along the granulocytic cell lineage. Note that no alteration of RAR or RXR expression or integrity was observed in WY-1 cells (data not shown). Southern blotting with a PCR-amplified retrovirus fragment as probe indicated that a single LXSN retrovirus (schematically illustrated in Figure 3a ) copy is present in the WY-1 genome (Figure 3c, left) . Ligation-mediated PCR-based genome walking localized the virus at position 130 629 014 (Figure 3b ) at the chromosomal locus 8q24.21, about 200 kb downstream of the closest known gene, melanoma-derived leucine zipper extranuclear factor (MLZE). Southern blotting with Ase I-restricted DNA confirmed the single copy integration at this locus, as a PCR-generated genomic fragment of PLB985 DNA (Figure 3b ) hybridized to 1.4 and 4.9 kb fragments of WT and WY-1 DNA, respectively, corresponding to the addition of the 3.5 kb virus sequence in WY-1 DNA (Figure 3c , right panel).
The insertion occurred in the putative first intron of a gene (gene ID: 137196) whose function is unknown and subsequently referred to as RAM. RAM is a hypothetical 328 546 bp-spanning gene comprising four exons that encode a 1718 bp transcript ( Figure 4a ). EST data confirmed RAM expression, which is highly restricted (bone marrow, spleen, testis, eye, heart, kidney, skin); during development, RAM is predominantly expressed in the embryo. Surprisingly, RAM has a short open reading frame (ORF) encoding a peptide of only 109 amino acids, which does not exhibit any predictable motifs, domains or features ( Figure 4b ). There is yet no evidence supporting the expression of the predicted RAM protein.
Whereas no known gene in the vicinity of the insertion site (up to 1 Mb) is found to be controlled by RA or involved in RA signaling or apoptosis, RAM itself is negatively regulated by RA in both PLB985 ( Figure 4c , 'WT') and NB4 cells (Figure 4d ). Interestingly, WY-1 cells expressed higher basal level of RAM mRNA than PLB985 cells (compare the '0' lanes in Figure 4c) , suggesting that the inserted retrovirus enhanced RAM transcription. Indeed, RAM expression in PLB985 cells is extinguished after 10 days of 9-cis RA exposure, whereas WY-1 cells show a reduction but retain a significant RAM mRNA level even after 14 days of treatment ( Co-resistance to 9-cis RA and TRAIL W Yin et al cancer or Jurkat T cells ( Figure 4e ). Thus, RAM may constitute a marker for this lineage or even play a role in myelopoiesis.
9-cis RA activates TRAIL death pathway in PLB985 but not in WY-1 cells 9-cis RA activated the extrinsic death pathway, as shown by the autocatalysis of procaspase-8 that generates an indicative pattern of peptides (p43, p41, p18) (Sprick et al., 2002) as the positive control TRAIL (Figure 5a , top panel). Not surprisingly, both 9-cis RA and TRAIL cleave PARP, one of the downstream targets of the caspase cascade ( Figure 5a , bottom panel).
As the extrinsic death pathway is activated by several death receptors, we used RNase protection assay to study potential effects of 9-cis RA on the expression profiles of TNFa, FasL, TRAIL and their receptors A fragment of LXSN amplified by PCR (using P-1 and P-2 as primers) and a genomic DNA fragment (PCR with P-3 and P-4 as primers on wild-type PLB985 DNA) encompassing the LXSN insertion site were used as probes for Southern blot; linearized pLXSN (L, 10 pg; H, 100 pg probe) was used as the positive control; the depicted markers correspond to sizes of 10, 8, 6, 5, 4, 3.5, 3, 2, 1.5, and 1 kb. b c d e atg gaa aga ttg tgc ctg cag cct ggc ctg ttg ccc aca gcg gtc tac ctg cca cac tgg gaa aga tcg agc aga gac aga gaa gaa aag gag gct cca ttt ttc agg ctg ctc tcc cgc agg ctc atg ttt tgt gtt cat gcc agg cag aga aca caa aat gtt cca ata aat aag tat caa agg tta gtg gtg aaa atg aag gag gaa gag gca ttg cgt gaa aaa cta aac atg caa aat att aca cac aaa gag aac caa aat gca ggt tca ctg gaa atg ata gac aat atg tta aaacaa gag gag aga aga gag ctg aaa taa Co-resistance to 9-cis RA and TRAIL W Yin et al ( Figure 5b ). In PLB985 ('WT') cells, the expression of FasL and Fas was barely detectable, which largely excludes their involvement in the 9-cis RA apoptotic signaling. In contrast, the mRNA levels of both TNFa (data not shown) and TRAIL were strongly induced. TRAIL mRNA level started to increase at day 4 and peaked at day 8 (Figure 5b, lanes 6-10) , correlating with the kinetics of apoptosis. Moreover, also the expression of the cognate receptors DR4 and DR5 was upregulated, whereas DcR1 mRNA levels increased only transiently upon treatment. In keeping with the mRNA data immunoblotting confirmed strongly increased TRAIL protein expression (Figure 5c ). In WY-1 cells hardly any effects of 9-cis RA on the expression of TRAIL, DR4, DR5 and DcR1 were discernible (Figure 5b, lanes 1-5) . Together these data support an implication of the TRAIL or TNFa, but not FasL, death pathways in 9-cis RA-induced apoptosis.
WY-1 cells are co-resistant to TRAIL Whereas TNFa did not induce PLB985 apoptosis (data not shown), recombinant TRAIL caused massive cell death within 12 h (Figure 6a ). Most interestingly, the 9-cis RA-resistant WY-1 cells exhibited co-resistance to TRAIL (Figure 6b ). We have previously established that PLB985 are type-II cells (see introduction) in which TRAIL activates also the mitochondrial death pathway (our unpublished observations). In keeping with the above TRAIL resistance, no alteration in the mitochondrial membrane potential could be observed in WY-1 cells upon exposure to RA, while there was an obvious loss of mitochondrial membrane potential in WT cells (Figure 6c ). This data suggest that RAM is involved not only in 9-cis RA-induced differentiation and postmaturation apoptosis but also in TRAIL-induced cell death.
TRAIL siRNA inhibits 9-cis RA-induced apoptosis To confirm the critical requirement of TRAIL in 9-cis RA-induced PLB985 cell apoptosis, we used a 21-nt small interfering RNA (siRNA) to knock down TRAIL expression. Whereas a scrambled siRNA showed little effect, the TRAIL-specific siRNA inhibited about 45% of 9-cis RA-induced apoptosis (Figure 6d, top) . This corresponds to 75% in the transfected cells. Since the efficiency of transfection was determined with a FITCconjugated oligonucleotide to correspond to about 60% (data not shown). Western blots confirmed that TRAIL siRNA indeed diminished TRAIL protein expression (Figure 6d, bottom) . We conclude from this data that TRAIL induction is critically involved in 9-cis RAinduced post-maturation PLB985 cell apoptosis. Co-resistance to 9-cis RA and TRAIL W Yin et al
Knockdown of RAM expression promotes 9-cis RAinduced differentiation and TRAIL-triggered apoptosis
To assess the role of RAM on cell differentiation and apoptosis, we used siRNA-mediated RNA interference. Importantly, silencing RAM expression in both PLB985 and WY-1 cells (Figure 7a ) promoted 9-cis RA-induced differentiation and TRAIL-triggered apoptosis in both cell lines (Figure 7b and c), indicating that RAM expression antagonizes PLB985 differentiation and cell death.
As the RAM-directed siRNA is expected to impair the expression of both the 1718 bp RAM transcript and the predicted 109-residue RAM protein, we decided to test the effect of the exogenously overexpressed epitopetagged RAM ORF on retinoic acid (RA)-induced cell differentiation and death. The aim was to distinguish effects exerted by the RAM RNA from effects, if any, of the predicted protein. For this we first confirmed Co-resistance to 9-cis RA and TRAIL W Yin et al expression of a stably expressed B10 epitope-tagged RAM in H3396 breast cancer cells by immunoblotting. Surprisingly, using the identical construct with PLB985 cells, we were able to detect RNA derived from the RAM ORF cDNA by RT-PCR, but not the corresponding protein, thus suggesting a decreased stability of the predicted RAM protein in PLB985 relative to H3396 cells (data not shown). The different stability was not due to a PLB985 cell-specific instability of the B10 epitope tag, as virtually the same result was obtained with a lentivirally overexpressed RAM fused to the V5-epitope (Figure 7d ; note also the expression of endogenous RAM mRNA in the 'À' lane, middle panel). Overexpression of the RAM ORF cDNA did not exert any notable effects on the 9-cis RA-induced differentiation and apoptosis in PLB985 cells (Figure 7e and f) nor did it affect the growth or apoptosis of H3396 cells, where the RAM protein was well expressed (data not shown). These results indicate a dichotomy between the roles of the 1718 bp RAM transcript and the RAM ORF cDNA and/or its encoded protein. The fact that the RAM protein expressed from the RAM ORF cDNA is unstable in PLB985 cells while the corresponding mRNA is well expressed, suggests that also the endogenous protein may be unstable, or not expressed at all. It is therefore tempting to speculate that the endogenous RAM transcript, whose expression in multiple tissues is confirmed by EST data (see above), may have functions that are unrelated to the short ORF encoded in its sequence. Provided that additional studies solidify this exciting hypothesis, the RAM transcript would be the first RNA modulator of RA-induced myeloid differentiation and apoptosis.
Discussion
Increasing evidence supports the idea that the induction of tumor-selective TRAIL together with the activation of its cognate receptors contributes to the successful treatment of APL patients by combined treatment with RA and chemotherapy Altucci and Gronemeyer, 2004) . To study whether retinoids can induce TRAIL also in cells devoid of PML-RARa, we chose the myelomonoblastic PLB985 (Tucker et al., 1987) cell model to define the individual actions of RAR isotype and RXR-selective ('rexinoids') retinoids on differentiation, proliferation and apoptosis. Our results fully confirm that both retinoids and rexinoids are required to induce apoptosis in these cells (Monczak et al., 1997) , which differs fundamentally from promyelocytic NB4 cells that require only RARa-selective agonists for both maturation and apoptosis (Chen et al., 1996) , suggesting that PML-RARa expression may obliterate the additional requirement for RXR activation. However, also in PLB985 cells RARadependent maturation is prerequisite for RXR-selective ligands to induce cell death. Together with earlier data on HL60 (Nagy et al., 1995) these results exclude very clearly that apoptosis is by default a consequence of RARa-dependent cell differentiation along the granulocyte lineage. Indeed, we have previously provided evidence for distinct activities of RAR and RXR (Chen et al., 1996) and it is tempting to speculate that different RXR heterodimer(s) may trigger maturation (e.g. retinoid-activated RARa-RXR) and post-differentiation apoptosis (e.g. one or more permissive RXR heterodimers, such as PPAR-RXR or alike).
To identify factor(s) critically involved in differentiation and/or apoptosis induced by the retinoid-rexinoid combination, we employed a retrovirus insertion mutagenesis-mediated gene trap approach, established and characterized in detail one mutant PLB985 cell-line (WY-1) that is resistant to the dual RAR, RXR agonist 9-cis RA. The mutant cells are partially defective for differentiation as RA-induced CD11 marker expression is strongly decreased and NBT reduction, a classical test for efficient maturation is virtually negative. Note that WY-1 are selectively defective in retinoid-induced differentiation, as monocytic differentiation by vitamin D3 exposure is unaffected. Importantly, WY-1 is not only resistant to 9-cis RA but also to TRAIL-induced apoptosis, suggesting that the virus integration has activated a survival pathway or, inactivated a factor that is required for both 9-cis RA and TRAIL-induced apoptosis.
Mapping the LXSN integration site resulted in the identification of a poorly annotated gene, RAM, whose function(s) were entirely unknown. Several arguments support that virus integration in RAM is the cause of the altered differentiation and apoptosis characteristics of PLB985, (i) our expression analyses show that RAM is a RA-regulated gene (ii) that is expressed in immature cells of the myeloid lineage and silenced by RA in PLB985 cells but (iii) owing to viral LTR enhancer WY-1 cells retain considerable RAM expression even after long-term exposure to RA. It is highly unlikely that selection of the retrovirus-infected cells resulted in the isolation of a cell that is resistant to 9-cis RA and just fortuitously carried a single virus inserted in a RAregulated myeloid-specific gene. It is similarly unlikely that the insertion has affected the expression of another gene, as the next hypothetical gene downstream of RAM is nearly 1 Mb away and the first exon of the closest downstream gene, MLZE (Watabe et al., 2001) , which is expressed primarily in human trachea and spleen, is more than 200 kb away from the retrovirus insertion (see Figure 4a) . A scan of 60 kb around the first exon of RAM identified only three putative RA response elements (1124 bp upstream DR2: AGGTCAggAG TTCG; 6207 bp upstream DR2: AGGTCAggAGTTCA; 12 965 bp upstream DR5: AGTTCAactccAGGTCA on the positive strand), which may mediate the RA response. Interestingly, all three elements are of the G/ T type, which displays anisotropic RAR-RXR binding (Mader et al., 1993) . It will be interesting to study if this type of response element architecture mediates negative regulation by RA.
Expression of the 1718 bp RAM transcript, covering all four exons is confirmed by EST data. Unexpectedly in view of its size, RAM can only encode a 109-residue Co-resistance to 9-cis RA and TRAIL W Yin et al basic peptide (13.192 Da, theoretical pI 9.51), which displays no predictable motifs other than a 17-residue signal peptide (InterProScan, EBI). Knockdown of RAM expression by siRNA did not activate cell differentiation or cell death on its own, but promoted 9-cis RA-induced differentiation and TRAIL-triggered apoptosis, demonstrating an important role of RAMencoded functions in regulating the RA program in PLB985 cells. Astonishingly, overexpression of the epitope-tagged reconstructed ORF generated the corresponding mRNA, but the 109-residue protein was undetectable in PLB985 cells albeit it was readily detected from the identical construct in breast cancer cells, where it is normally not expressed (see above). Therefore in myeloid cells, which express the 1718 bp RAM transcript endogenously, translation of the small ORF may be inefficient/suppressed or the corresponding peptide may be rapidly degraded. It is thus tempting to speculate that the ORF coding capacity is irrelevant for the differentiation and apoptosis-inhibitory function of the mature RAM transcript in myeloid cells and that the full-length transcript acts as the first putative RNA modulator of a RA-induced gene program.
Together with our previous work the present study emphasizes once again the central role of TRAILmediated tumor-selective death signaling in the anticancer action of retinoid, rexinoids and even novel epigenetic drugs (Altucci et al., , 2005 Clarke et al., 2004; Insinga et al., 2005; Nebbioso et al., 2005; Yin et al., 2005) . Our data reveal a link between cell maturation, apoptosis and TRAIL signaling which is at first sight puzzling in view of the well-established apoptogenic action of TRAIL. However, it is being increasingly documented that TRAIL has signaling capacity beyond the mere induction of apoptosis. Indeed, TRAIL itself is a regulator of cell differentiation and has been reported to promote NFkB-dependent maturation of myeloid cells (Secchiero et al., 2003) . Moreover, the crosstalk between TRAIL and NFkB signaling pathways is well established Baetu et al., 2001; Bernard et al., 2001; Ravi et al., 2001) . Interestingly, we have observed that NFkB signaling is dramatically deregulated in WY-1 cells (our unpublished data) which could suggest that RAMassociated functions may act as key regulators at the node of multiple signaling crosstalks that impact on cell survival, differentiation and death.
Materials and methods

Reagents
Recombinant human TRAIL and anti-TRAIL antibody were from R&D (Minneapolis, MN, USA); antibodies against caspase-8 and cleaved PARP were from Cell Signalling Technology (Beverly, MA, USA); phycoerythrine (PE)-conjugated anti-CD11c and FITC-conjugated anti-CD14 antibodies were from PharMingen (San Diego, CA, USA); antibody for b-actin was from Santa Cruz (Santa Cruz, CA, USA); FITC-conjugated Annexin-V was from CALTAG Laboratories (Burilingame, CA, USA); 1a,25-dihydroxyvitamin D3 (VD3) was from Calbiochem (San Diego, CA, USA), BMS753, SR11237 and 9-cis RA were provided by BristolMyers Squibb (Princeton, NJ, USA) and used at 10
Cell culture, retinoic acid treatment and retroviral infection PLB985 and NB4 cells were grown in RPMI 1640 medium containing 10% FCS. For LXSN retrovirus production, the amphotropic packaging PA317 cells were transfected with pLXSN by calcium phosphate co-precipitation. PLB985 cells were infected with the retrovirus-containing supernatant at MOI of 1:1 and subjected to 800 mg/ml of neomycin selection for 2 weeks. The neomycin-resistant cells were then exposed to 1 mM 9-cis RA for 3 weeks. From the double-resistant cells, one cell line (termed as WY-1) was established.
LM-PCR, Southern blot and sequence analysis Ligation-mediated PCR was performed using the TOPO Walker Kit (Invitrogen). Briefly, the genomic DNA was first digested with Pst I, then primed by a LXSN LTR primer (5 0 -CCGCCAGATACAGAGCTAGTTAGC-3 0 ) to create double-stranded molecules with 3 0 A-overhangs, which were later ligated to a TOPO Linker. These linked molecules were amplified by PCR using another LTR primer (5 0 -GACGCAG TCTATCGGAAGACTGGC-3 0 ) and a linker primer (provided with kit). Taking the PCR products as templates, a nested PCR was performed using a nested LTR primer (5 0 -TC ACTCAGCTGTCTCATCTGTTCT-3 0 ) and a nested linker primer (provided with kit), which yielded an 800 bp fragment containing part of LTR of LXSN and 508 bp of PLB985 genomic DNA. Localization of the retrovirus insertion site was done by analysis of the 508 bp sequence by BLAST (blast@ncbi.nlm.nih.gov). For Southern blot, Ase I-digested DNA was electrophoresised on 0.7% agarose gel and blotted onto Hybond-N þ membrane (Amersham Pharmacia). A fragment of pLXSN amplified by PCR using P-1 and P-2 (see Figure 3a ; P-1, 5 0 -CTGAGCTATTCCAGAAGTAGTGAG-3 0 ; P-2, 5 0 -CAGGTAGCCGGATCAAGCGTATGCAGC-3 0 ) and a PCR-amplified genomic fragment encompassing the retrovirus insertion site (using P-3 and P-4 depicted in Figure 3b ; P-3, 5 0 -GGCCACTTTTGGAGAGTCCGACTA-3 0 ; P-4, 5 0 -GCAGA GGCCAAGGCTAGTTGTCTT-3 0 ) were labelled with digoxigenin and used as probes for Southern blots (DIG Easyhyb system; Roche Mol Biochem, Indianapolis, IN, USA).
Semi-quantitative RT-PCR and RNase protection assay
In RT-PCR, 2 mg of total RNA (extracted using TRIzol (GIBCO)) was used to synthesize cDNA using oligo(dT) 15 as primer. Identical quantities of cDNA were used for PCR (RAM specific primers, sense: 5 0 -ATGGAAAGATTGTGCC TGCAG-3 0 , antisense, 5 0 -TTATTTCAGCTCTCTTCTCTC-3 0 ; V5 primer, antisense: 5 0 -ACCGAGGAGAGGGTTAGGG AT-3 0 . PCR was performed for 25-30 amplification cycles at an annealing temperature of 601C. As control, either b-actin or L32 cDNA were simultaneously amplified with the following primers: b-actin, sense, 5 0 -CCTCGCCTTTGCCGATCCGCC-3 0 and antisense, 5 0 -GGATCTTCATGAGGTAGTCAGTC-3 0 ; L32, sense, 5 0 -GCTGCCTACGGAGGTGGCAGCCATC TCCTT-3 0 , antisense, 5 0 -GAAGGAAGATGCCAGATGGC AGTTTTTAC-3 0 . RNase Protection Assays were performed with RiboQuant RPA template sets (BD PharMingen, Franklin Lakes, NJ, USA) according to the instructions provided.
Western-blot analysis Total cellular protein was prepared using RIPA lysis buffer (150 mM NaCl, 10 mM Tris-HCl pH 7.5, 1 mM EDTA, 1% NP-40, 1 mM DTT, 20 mg/ml leupeptin, 10 mg/ml pepstatin, 10 mg/ml aproptinin, 1 mM PMSF). Proteins were separated by SDS acrylamide gel electrophoresis and transferred to BA85 nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) and probed by antibodies as indicated. ECL detection kit (Amersham) was used for visualization.
Flow cytometry
For Annexin-V staining, 2.5 Â 10 5 cells were resuspended in 50 ml HEPES buffer (10 mM HEPES/NaOH pH 7.4, 150 mM NaCl, 1 mM MgCl 2 , 5 mM KCl, 1.8 mM CaCl 2 ) containing 1 ml Annexin-V-FITC and kept for 15 min in dark at room temperature. HEPES buffer containing 0.25 mg/ml propidium iodide (PI) was added before analysis by FACScan. For cellcycle analysis, 2.5 Â 10 5 cells were resuspended in 500 ml hypotonic buffer (0.1% Triton X100, 0.1% sodium citrate, 50 mg/ml PI), incubated in dark over night at 41C and subjected to FACScan analysis. In differentiation assays, 2.5 Â 10 5 cells were incubated with 10 ml PE-conjugated anti-CD11c antibody in dark on ice for 30 min. Cells were washed, resuspended in PBS with 0.25 mg/ml PI and subjected to flow cytometry. Mitochondrial membrane potential was assayed by incubating 2.5 Â 10 5 cells with 50 nM DiOC6(3) for 30 min in the dark and subsequent examination by flow cytometry.
NBT reduction assay Medium (500 ml) containing 1 Â 10 6 cells was mixed with 500 ml solution containing 0.2% nitroblue tetrazolium (NBT) and 200 ng 12-O-tetradecanoylphorbol-13-acetate (TPA; SIGMA), after incubation for 30 min at 371C, 500 ml lysis buffer (50% Dimethylformamide, 20% SDS, pH 7.4) was added and OD was measured at 570 nm.
RNA interference TRAIL siRNA kindly designed and provided by Ana JimenezLara, was synthesized at Dharmacon Research, Inc. (Lafayette, CO, USA). The sequences are for sense siRNA, 5 0 -AACGAGCUGAAGCAGAUGCAGdTdT-3 0 and for antisense siRNA, 5 0 -CUGCAUCUGCUUCAGCUCGUUdTdT-3 0 . siRNA transfection was performed with Oligofectamine (Life Technologies). The siRNAs were applied daily to the PLB985 cultures at final concentration of 200 nM after 4 days of treatment with 9-cis RA. At day 8, the cells were harvested for FACS analysis or Western-blot experiments. RAM siRNA was prepared using the Silencert siRNA Cocktail kit (RNaseIII) essentially as described by the manufacturer (Ambion Inc., Austin, TX, USA). Primers containing T7 promoter sequence for generating RAM dsRNA are: sense, 5 0 -TAATACGACTCACTATAGGGAAAGATTGTGCCTGCA GCCTG-3 0 and antisense, 5 0 -TAATACGACTCACTATAGG GAGCTCTCTTCTCTCCTCTTGT-3 0 . Cells in 24-well plates were transfected with RAM siRNA (50 nM) by Lipofectaminet2000 (Life Technologies) and/or treated by TRAIL or 9-cis RA as indicated before subjecting to RT-PCR or flow cytometry analysis.
Lentiviral expression of exogenous RAM ORF in PLB985 cells
The Virapower lentiviral expression system (Invitrogen) was used to produce the lentivirus coding for RAM/V5 protein following the provided instructions using the pLenti6-RAM/ V5 construct. Once collected, the lentivirus was concentrated by ultracentrifugation (25 000 r.p.m., 90 min, 41C). PLB985 cells were infected with the virus at a concentration of 2.10 6 IU/ml corresponding to a MOI of 20:1 and selected for stable integration with 10 mg/ml blasticidin.
